UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Does cancer that occurs during or after anti–tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site‐specific cancer survival in rheumatoid arthritis patients treated with biologic agents

Arthritis & rheumatology (Hoboken, N.J.), 2011-07, Vol.63 (7), p.1812-1822

2011

Volltextzugriff (PDF)

Chronic widespread musculoskeletal pain – A comparison of those who meet criteria for fibromyalgia and those who do not

European journal of pain, 2008-07, Vol.12 (5), p.600-610

2008

Volltextzugriff (PDF)

Ten years with biologics: to whom do data on effectiveness and safety apply?

Rheumatology (Oxford, England), 2011-01, Vol.50 (1), p.204-213

2011

Volltextzugriff (PDF)

Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?

Annals of the rheumatic diseases, 2015-06, Vol.74 (6), p.1212-1217

2015

Volltextzugriff (PDF)

Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register

Annals of the rheumatic diseases, 2015-05, Vol.74 (5), p.890-896

2015

Volltextzugriff (PDF)

Prevalence of widespread pain and associations with work status: a population study

BMC musculoskeletal disorders, 2008-07, Vol.9 (1), p.102-102, Article 102

2008

Volltextzugriff (PDF)

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

The Lancet (British edition), 2012, Vol.379 (9827), p.1712-1720

2012

Volltextzugriff (PDF)

Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial

Annals of the rheumatic diseases, 2011-03, Vol.70 (3), p.469-475

2011

Volltextzugriff (PDF)

Belimumab may not prevent lupus nephritis in serologically active patientswith ongoing non-renal disease activity

Scandinavian journal of rheumatology, 2014, Vol.43 (5), p.428

2014

Volltextzugriff (PDF)

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

The Lancet (British edition), 2009-08, Vol.374 (9688), p.459-466

2009

Volltextzugriff (PDF)

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

Annals of the rheumatic diseases, 2009-05, Vol.68 (5), p.648-653

2009

Volltextzugriff (PDF)

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

Annals of the rheumatic diseases, 2005-10, Vol.64 (10), p.1421-1426

2005

Volltextzugriff (PDF)

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission

Rheumatic & musculoskeletal diseases open, 2016-01, Vol.2 (1), p.e000133-e000133

2016

Volltextzugriff (PDF)

The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study

Arthritis research & therapy, 2014-01, Vol.16 (3), p.R127-R127

2014

Volltextzugriff (PDF)

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

Annals of the rheumatic diseases, 2005-10, Vol.64 (10), p.1414-1420

2005

Volltextzugriff (PDF)

Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study

BMJ open, 2012-01, Vol.2 (5), p.e001524

2012

Volltextzugriff (PDF)

Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register

Annals of the rheumatic diseases, 2011-03, Vol.70 (3), p.516-519

2011

Volltextzugriff (PDF)

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden

BMJ (Online), 2013-04, Vol.346 (apr08 1), p.f1939-f1939

International edition, 2013

Volltextzugriff (PDF)

Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?

Arthritis and rheumatism, 2009-11, Vol.60 (11), p.3180-3189

2009

Volltextzugriff (PDF)

Anti-TNF therapy in RA and risk of malignant lymphomas Relative risks and time-trends in the Swedish Biologics Register

Annals of the rheumatic diseases, 2008, Vol.68 (5), p.648

2008

Volltextzugriff (PDF)

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

Arthritis and rheumatism, 2005-07, Vol.52 (7), p.1986-1992

2005

Volltextzugriff (PDF)

Proteoglycan biosynthesis in cultures of corneas and corneal stroma cells from adult rabbits

Experimental eye research, 1978-08, Vol.27 (2), p.175-190

1978

Volltextzugriff (PDF)

Ten years with biologics: to whom do data on effectiveness and safety apply?: Registries in Rheumatological and Musculoskeletal Conditions

Rheumatology (Oxford, England), 2011, Vol.50 (1), p.204-213

2011

Volltextzugriff (PDF)

Altered dermatan sulfate proteoglycan synthesis in fibroblast cultures established from skin of patients with systemic sclerosis

Journal of rheumatology, 1996-08, Vol.23 (8), p.1398

1996

Volltextzugriff (PDF)

Rheumatoid Arthritis: Insights, Strategies And Expectations? Swedish Results Of The Raise Patient Needs Survey

Scandinavian Journal of Rheumatology, 2010, Vol.39, p.23

2010

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(46)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(35)
Humans
(31)
Medicin Och Hälsovetenskap
(29)
Female
(25)
Male
(24)
Clinical Medicine
(23)
Klinisk Medicin
(23)
Medical And Health Sciences
(23)
Middle Aged
(23)
Rheumatology
(20)
Aged
(19)
Adult
(17)
Arthritis, Rheumatoid - Drug Therapy
(17)
Biological And Medical Sciences
(16)
Reumatologi Och Inflammation
(16)
Rheumatology And Autoimmunity
(16)
Tumor Necrosis Factor-Alpha - Antagonists & Inhibitors
(15)
Antirheumatic Agents - Therapeutic Use
(14)
Medical Sciences
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Does cancer that occurs during or after anti–tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site‐specific cancer survival in rheumatoid arthritis patients treated with biologic agents

Chronic widespread musculoskeletal pain – A comparison of those who meet criteria for fibromyalgia and those who do not

Ten years with biologics: to whom do data on effectiveness and safety apply?

Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?

Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register

Prevalence of widespread pain and associations with work status: a population study

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial

Belimumab may not prevent lupus nephritis in serologically active patientswith ongoing non-renal disease activity

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission

The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study

Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden

Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?

Anti-TNF therapy in RA and risk of malignant lymphomas Relative risks and time-trends in the Swedish Biologics Register

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

Proteoglycan biosynthesis in cultures of corneas and corneal stroma cells from adult rabbits

Ten years with biologics: to whom do data on effectiveness and safety apply?: Registries in Rheumatological and Musculoskeletal Conditions

Altered dermatan sulfate proteoglycan synthesis in fibroblast cultures established from skin of patients with systemic sclerosis

Rheumatoid Arthritis: Insights, Strategies And Expectations? Swedish Results Of The Raise Patient Needs Survey

Suchergebnisse filtern